Chimeric mAbs were less evident ... this class of mAbs has been the main source of antibody-based products entering clinical studies since 1997. Figure 1: Number of mAbs entering clinical studies ...

to bispecific antibodies and chimeric antigen receptors for cell-based therapies. RubrYc’s collaboration model includes options for co-discovery and co-development programs, for out-licensing or ...

Chimeric antigen receptor-T (CAR-T) cell therapy ... (2) These cells are activated using anti-CD3/CD28 antibodies to stimulate their proliferation. (3) Genetic modification of the T cells is performed ...

Equities research analysts at StockNews.com began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a research report issued to clients and investors on Tuesday. The ...

The human anti-mouse antibody (HAMA) reaction limits the therapeutic utility of mouse monoclonal antibodies. Humanization of mouse monoclonal antibodies by genetic engineering can improve the in ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...